Live feed08:00:00·4dPRReleasevia QuantisnowArcutis Submits Supplemental New Drug Application to the FDA for ZORYVE® (roflumilast) Cream 0.05% to Expand Indication for Treatment of Atopic Dermatitis to Infants Down to 3 MonthsByQuantisnow·Wall Street's wire, on your screen.ARQT· Arcutis Biotherapeutics Inc.Health Care
